IL22RA1

Across TCGA pan-cancer cohorts, IL22RA1 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated IL22RA1 data layer compared with 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IL22RA1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated IL22RA1 expression acts as an unfavorable survival marker, although some lineages such as COAD and SARC show a favorable association.

LUAD, LGG, and UVM are the cancer types where IL22RA1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.597	0.725	<.001	87	view →
LGG	DFS	Median	All	0.653	0.816	<.001	54	view →
UVM	DFS	Quartile	All	0.417	0.667	.010	42	view →
COAD	OS	Quartile	IV	0.964	0.505	.001	34	view →
MESO	OS	Median	III,IV	0.437	0.693	.002	28	view →
UCEC	OS	Median	All	0.579	0.781	.004	26	view →
SARC	OS	Quartile	All	0.646	0.393	<.001	25	view →
PAAD	OS	Quartile	All	0.361	0.642	.004	21	view →
KIRP	OS	Quartile	II,III,IV	0.842	0.410	.006	21	view →
BRCA	OS	Median	II,III,IV	0.932	0.890	.009	20	view →
KICH	DFS	Tertile	II,III,IV	0.520	0.886	.017	19	view →
HNSC	OS	Median	III,IV	0.276	0.392	.003	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

IL22RA1–LUAD (DFS)

Open the LUAD breakdown →